(0.33%) 5 116.77 points
(0.32%) 38 362 points
(0.38%) 15 988 points
(-0.97%) $83.04
(5.56%) $2.03
(0.32%) $2 354.60
(0.42%) $27.65
(4.09%) $959.85
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe...
Stats | |
---|---|
本日の出来高 | 73 074.00 |
平均出来高 | 94 166.00 |
時価総額 | 82.99M |
EPS | €0 ( 2024-03-28 ) |
次の収益日 | ( €-1.860 ) 2024-05-28 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.720 |
ATR14 | €0.0320 (0.59%) |
ボリューム 相関
Affimed NV 相関
10 最も負の相関 | |
---|---|
ADBE | -0.958 |
FTIV | -0.953 |
PTMN | -0.951 |
WDAY | -0.946 |
MURFU | -0.946 |
NEWT | -0.944 |
ATLCP | -0.943 |
AMWD | -0.942 |
TATT | -0.942 |
AGNCO | -0.941 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Affimed NV 相関 - 通貨/商品
Affimed NV 財務諸表
Annual | 2023 |
収益: | €8.28M |
総利益: | €8.28M (100.00 %) |
EPS: | €-7.09 |
FY | 2023 |
収益: | €8.28M |
総利益: | €8.28M (100.00 %) |
EPS: | €-7.09 |
FY | 2022 |
収益: | €41.35M |
総利益: | €41.35M (100.00 %) |
EPS: | €-0.600 |
FY | 2021 |
収益: | €40.37M |
総利益: | €0.00 (0.00 %) |
EPS: | €-0.480 |
Financial Reports:
No articles found.
Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。